# Neo Kuma Ventures

Neo Kuma Ventures is a Venture Capital based in London, United Kingdom.

## Overview

- **Organization type:** Venture Capital
- **Headquarters:** London, United Kingdom
- **Region:** Europe
- **Address:** 71-75 Shelton Street, Covent Garden, London WC2H 9JQ, United Kingdom
- **Founded:** 2020
- **Assets under management:** Undisclosed
- **Website:** neokuma.co
- **LinkedIn:** https://www.linkedin.com/company/neo-kuma-ventures

## Regulatory record

- **Reports private funds:** No

## About

Neo Kuma Ventures is a venture capital firm investing in biotech and life sciences companies. The firm's investors bring transactional, VC, intellectual property, and operational experience. Its team includes professionals with backgrounds in law, private equity, and entrepreneurship.

## Sectors

- Biotech
- Life Sciences

## People

- Clara Burtenshaw — Investor
- Sean McLintock — Investor
- Fergus Argyle — Investor
- Dr. Peter Crane — Venture Partner
- Dr. Willem Hendrik Gispen — Venture Partner
- Isabel Fox — Advisory Board
- Lomax Ward — Advisory Board
- Christina Sass — Advisory Board

## Questions

### What is Neo Kuma Ventures' investment mandate?

The firm invests exclusively in early-stage psychedelic healthcare companies across three categories: compounds, clinics and care delivery, and digital therapeutics. Its geographic focus is global with a European tilt, writing cheques between £150k and £1m from pre-seed to Series A (per firm website). Neo Kuma does not invest outside these categories or stages.

### How does Neo Kuma Ventures source proprietary deal flow?

Neo Kuma emphasizes its specialist network, with relationships in the psychedelic sector going back 15 years. The firm's advisory board includes Outsized Ventures General Partners Isabel Fox and Lomax Ward, as well as Andela co-founder Christina Sass. By operating as the largest Europe-dedicated venture fund in psychedelics, the firm positions itself as a hub that sees most early-stage deal flow in its niche before generalist investors (per firm website, Altss estimate).

### Is Neo Kuma Ventures regulated?

Yes. Neo Kuma Ventures LLP is an Appointed Representative of The Fund Incubator Limited, which is authorised and regulated by the UK Financial Conduct Authority (FRN 208716) (per firm website). The firm is structured as an early-stage venture vehicle, not a multi-strategy asset manager.

### Which portfolio companies has Neo Kuma Ventures disclosed?

The firm lists Atai Life Sciences, Beckley Psytech, Bright Minds Biosciences, Kanna Health, Small Pharma, Journey Clinical, Wavepaths, Awakn Lifesciences, Sana Health, Monument Therapeutics, Tripp and Neurocentrx among its portfolio (per firm website). These span the firm's three investment categories: compounds, clinics and care delivery, and digital therapeutics.

### What investment stages does Neo Kuma Ventures target?

Neo Kuma writes its initial cheques from pre-seed to Series A, with an average ticket size of £150k to £1m (per firm website). The firm does not indicate participation in later-stage or growth rounds.

## Related profiles

- [NEO Investment Partners](https://altss.com/profile/neo-investment-partners)
- [NeoMed](https://altss.com/profile/neomed)

---

Last updated: 2026-07-10T08:09:05.000Z

Canonical page: https://altss.com/profile/neo-kuma-ventures

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology